Infinity Bio, Inc. is an innovative biotechnology company focused on providing advanced antibody profiling services. Established in 2023 and headquartered in Baltimore, Maryland, the company utilizes cutting-edge technology developed at Johns Hopkins University to address the complexities of antibody responses within the immune system.
MIPSA is Infinity Bio's proprietary technology designed for the intricate mapping of antibody reactivity against large libraries of antigens. This innovative platform allows for comprehensive profiling of antibodies, facilitating a deeper understanding of immune responses.
MIPSA addresses the critical challenge of understanding antibody responses, allowing researchers to gain insights that are vital for various applications in disease research and therapeutic development.
Infinity Bio addresses issues such as the need for comprehensive antibody characterization, efficient biomarker discovery, and the demand for reliable data in the context of vaccine development and autoimmune disease research.